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Dornase alfa has been shown to reduce markers of inﬂammation and neutrophil-associated metalloproteinases in cystic ﬁbrosis (CF), suggesting a
potential beneﬁt from use of this therapy early in the disease. However, observational studies indicate that dornase alfa is often reserved for “sicker”
patients. A 2-year, early intervention study of dornase alfa in CF patients with early lung disease demonstrated signiﬁcant improvements in lung
function and risk of exacerbation compared to placebo. A more recent analysis, using the database of the large observational Epidemiologic Study
of Cystic Fibrosis (ESCF), found that initiation of dornase alfa has the potential to alter the course of CF by decreasing the rate of lung function decline
in children and adults. These encouraging results, possibly linked to indirect effects on inﬂammation, suggest a greater role for dornase alfa therapy in
the early treatment of CF, where it may help preserve lung function and potentially extend survival.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Dornase alfa; Cystic ﬁbrosis; Inﬂammation; Pulmonary function
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which a progressive decline in pulmonary function is the major
source of mortality [1]. The lung destruction occurring in CF is
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doi:10.1016/j.jcf.2011.10.003an exaggerated inflammatory response [2,3]. Although treat-
ments aimed at relieving obstruction and treating infection
have long been the foundations of CF therapy, the recognition
of inflammation as an important driver of lung destruction has
focused greater attention on anti-inflammatory therapies [4].
Dornase alfa, a recombinant human deoxyribonuclease
(DNase), cleaves extracellular DNA in the airway to facilitate
mucus clearance in the lung [5]. It has been known for many
years that the accumulation and breakdown of neutrophils in
the infected lungs of CF patients leads to the release of large
amounts of DNA, which increases the viscosity of the infected
sputum and decreases ciliary transport [5,6]. By decreasing theby Elsevier B.V. All rights reserved.
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direct effect of relieving obstruction, which was the original
rationale for its development. Clinically, this translates into a
significant improvement in lung function for CF patients treated
with dornase alfa [7–9].
In addition to its effect on obstruction, dornase alfa also
significantly reduces the risk of exacerbations or infections
requiring intravenous antibiotics [7,9]. This may be linked to
reduced bacterial infection as a result of improved mucociliary
clearance [10], and/or broader effects on host defenses against
infection [11,12]. For example, a randomized 1-year trial of
dornase alfa (single-blinded to the clinical microbiologists)
reported a 30% prevalence of positive Staphylococcus aureus
cultures in untreated patients vs. 16% in the group treated
with dornase alfa (Pb0.0001) [10]. The study researcher attrib-
uted the reduced number of lower respiratory tract (LRT) path-
ogens in patients treated with dornase alfa to improved
mucociliary clearance and further speculated that reduced
LRT infection could be one of the mechanisms for the anti-
inflammatory effects of dornase alfa. Other study results,
however, have suggested that the action of dornase alfa may
have a more direct impact on infection rates by releasing anti-
microbial peptides bound in DNA/actin bundles in CF sputum
[11], as well as degrading bacterial extracellular matrix DNA,
which is an important proinflammatory component of bacterial
biofilms triggering neutrophil activation [12].
The observed clinical benefits on both obstruction and infec-
tion have led the Cystic Fibrosis Foundation to strongly recom-
mend dornase alfa for treatment in patients aged 6 years and
older with moderate to severe lung disease and to recommend
dornase alfa for treatment in patients aged 6 years and older
with mild lung disease to improve lung function and reduce
exacerbations [13].
The clinical efficacy of dornase alfa also may be related to
an indirect effect on enhanced early nutritional status in
young children with CF [14]. In a retrospective cohort study
of 165 infants using Cystic Fibrosis Foundation registry data
from 3 centers, prescription of dornase alfa prior to age 2 was
associated with a 10-percentile increase in body mass index
(BMI) through age 6 compared with infants not prescribed
dornase alfa. This result accounted for confounding factors,
such as demographics, CF center, age at diagnosis, and other
clinical factors, and use of supplemental feedings and pancreatic
enzymes. Nevertheless, the mechanisms of dornase alfa on nutri-
tional status and clinical implications of this finding are not yet
clear.
Despite clinical data demonstrating the efficacy of dornase
alfa in treating CF patients with early lung disease, data from
observational studies reflecting conventional clinical practice
demonstrate that it is often reserved for “sicker” patients, i.e.,
those with lower lung function, who are more likely to experi-
ence more frequent pulmonary exacerbations [15,16]. Recent
evidence indicates that dornase alfa can slow the rate of lung
function decline, and thus, may be beneficial if initiated earlier
in the course of the disease [17,18]. We speculate that the
ability of dornase alfa to modify the rate of lung function
decline may be related to its indirect effects on inflammationand by-products of the inflammatory cascade, including
neutrophil-derived proteases. This review examines the
evidence for anti-inflammatory effects of dornase alfa in the
CF lung and explores possible mechanistic links between this
anti-inflammatory activity and clinical benefit as they relate to
slowing disease progression.
1. Early inﬂammation in CF
The defective CF gene leads to defective or deficient CF
transmembrane conductance regulator (CFTR) protein and
thus abnormal salt and water transport. The resulting alterations
to mucus secretions and mucociliary clearance contribute to air-
way obstruction and set up a cycle of obstruction, infection, and
inflammation [3]. The exact order of events within this cycle
remains a matter of controversy, as there is evidence that
inflammation may actually precede infection or, alternatively,
may persist in the airway after the infection has been cleared
[3,4,19]. Nevertheless, it is clear that the neutrophil-driven
lung inflammation that characterizes CF begins very early in
the course of disease, becomes prolonged, and is disproportion-
ate to the burden of infection. Bronchoalveolar lavage (BAL)
fluid from infants with CF, for example, has been shown to
contain high levels of inflammatory markers, even in those
without active infection [20]; in those infected only with
Haemophilus influenzae, BAL fluid contains more neutrophils
and interleukin-8 (IL-8) than BAL fluid from infants who
have other chronic respiratory conditions and are infected
with H. influenzae[21,22].
Neutrophils are present in large quantities in the lungs of CF
patients even in infants and in older patients who are clinically
stable with early stage lung disease [20,23]. These neutrophils
initially function to control infection but, in doing so, release ox-
idants and proteases (e.g., elastase and matrix metalloproteinases
8 and 9 [MMP-8 andMMP-9]) that may destroy lung tissue when
they are present at high concentrations [2,24]. Elastase is also a
potent mucus secretagogue that increases airway obstruction
and contributes to the generation of neutrophil chemoattractants
such as interleukin-8 (IL-8), further amplifying the inflammatory
response. Finally, the decomposition of neutrophils leads to the
accumulation of extracellular DNA and actin in the airway,
increasing the viscosity of sputum and further hindering airway
clearance [2,25].
These findings, taken together, have prompted efforts to better
define the role of anti-inflammatory therapies for use earlier in the
course of CF lung disease [4].
2. Indirect anti-inﬂammatory effects of dornase alfa
The Bronchoalveolar Lavage for the Evaluation of Anti-
inflammatory Treatment (BEAT) study was a 3-year BAL
study conducted to assess the anti-inflammatory activity of
dornase alfa in patients with CF with early lung disease [26,27].
The study included 105 patients (mean age, 11.8 years) who
had a forced expiratory volume in 1 second (FEV1) of >80%
predicted and were clinically stable. After the first BAL, patients
with elevated neutrophil counts (>10% for children aged
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Fig. 1. Effect of dornase alfa on markers of inflammation over the 3-year BEAT study [26]. [reprint permission needed] Median neutrophils (% of total cell popu-
lation), interleukin-8 levels, and elastase activity in bronchoalveolar lavage fluid (BALF) of patients randomized to treatment with dornase alfa or no dornase alfa
treatment, at baseline and after 3 years.
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ized to dornase alfa (n=46) or no treatment (n=39). Twenty pa-
tients were not randomized due to lower neutrophil counts.
Follow-up BAL was performed after 18 and 36 months. During
the 3-year study period, the percentage of neutrophils in BAL
fluid significantly increased in untreated patients (Pb0.02)
while remaining constant in the dornase alfa group [Fig. 1].
Levels of elastase and IL-8 also significantly increased from
baseline in the untreated group (Pb0.007 and Pb0.02 for
elastase and IL-8, respectively) but remained stable in patients
receiving dornase alfa. Myeloperoxidase levels showed similar
trends but the changes were not statistically significant.
In a substudy of 23 patients participating in the BEAT study
(n=13, treated with dornase alfa; n=10, not treated), levels of
MMP-8 and MMP-9 were measured due to their central role
in CF airway inflammation and potential role in lung tissue de-
struction [24]. Compared with the BAL fluid of 11 children
without pulmonary disease, the BAL fluid of CF patients with
early lung disease showed a 300-fold increase in MMP-8 and
116-fold increase in MMP-9 levels. As shown in Fig. 2, after
18 months, patients treated with dornase alfa showed a decreaseFig. 2. Changes in MMP-9 concentrations in BAL fluid for patients who wfrom baseline in median MMP-8 and MMP-9 levels (−23 and
−20 ng/mL, respectively) while those not treated showed an in-
crease (15 and 16 ng/mL in MMP-8 and MMP-9 levels, respec-
tively; P=0.007 and P=0.02 for between-group differences). It
can therefore be speculated that by decreasing MMP levels
associated with lower airway inflammation, treatment with
dornase alfa may diminish long-term structural lung damage.
Another study that assessed airway inflammation after treat-
ment with dornase alfa [28] reported negative results that conflict
with the findings from the BEAT study. However, it was a short-
term study with an older patient population (mean age 16.8 years;
range 6.7–27.5 years) and other methodological differences
relative to the BEAT study. Briefly, 20 patients with CF were
treated for 1 month with dornase alfa, and sputum samples before
and after the 1-month trial were analyzed for total cell and neutro-
phil counts. There were no significant changes in cell counts after
dornase alfa treatment in either clinical responders (n=13) or
nonresponders (n=7). Mean FEV1 increased significantly,
however, from 62.3% predicted at baseline to 70.8% after
1 month of treatment (P=0.02), and 13 patients had a 10% or
greater increase in FEV1. The 1-month time scale (comparedere untreated (A) or treated with dornase alfa (B) over 18 months [24].
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group may have prevented this study from demonstrating the
anti-inflammatory effect of dornase alfa reported in the BEAT
study, which found increased levels of neutrophils over time in
the untreated patients vs. unchanged levels in the dornase alfa
group.Fig. 4. Mean change in FEV1 from baseline through 96 weeks in a study of children
with early-stage CF lung disease [9].3. Effect of dornase alfa on rate of lung function decline
In patients with CF, disease progression is assessed by plotting
their FEV1% predicted value vs. time [29]. The age at which this
curve intersects 20% predicted FEV1 is a strong predictor of
mortality, and a steeper slope indicates a more rapid rate of
lung function decline [29–31]. Although there is a high degree
of variability in the progression of CF lung disease, several risk
factors are known to predict the rate of decline in lung function
[32]. In particular, young patients with high lung function have
a significantly elevated risk of immediate rapid decline,
underscoring the need for early and aggressive treatment.
As shown in Fig. 3, therapies with the best chance of ulti-
mately improving patient survival would be those not only
providing immediate improvement in lung function but also
altering the underlying rate of decline in FEV1 (% predicted/
year) [17]. The BEAT study of dornase alfa in patients with
early lung disease of CF provided encouraging results in this
direction. Although the study was not designed to assess the ef-
fect of dornase alfa on decline in lung function, it demonstrated
a trend toward a slower rate of FEV1 decline over the 3-year
treatment period in those receiving dornase alfa vs. those not
treated (−1.99% predicted/year vs. −3.26% predicted/year,
respectively; P=not significant) [26].
The inherent difficulty in demonstrating an effect on the rate
of lung function decline in a clinical trial is that studies powered
to do so require several years' duration and/or a large number
of patients, even in the presence of a large therapeutic effect
[33,34]. This clinical reality is illustrated by the Pulmozyme
Early Intervention Trial (PEIT)—a 2-year longitudinal study
of 474 young CF patients (aged 6–10 years) with mean FEV1
of 95% predicted[9]. This study demonstrated a treatment
benefit with dornase alfa (Fig. 4), with the dornase alfa-
treated patients maintaining lung function over the 2-year
study period but the placebo group experiencing a mean de-
crease in FEV1 of 3.2% predicted from baseline (P=0.006,Fig. 3. Benefit of increasing forced expiratory volume in 1 second (FEV1) vs.
slowing the rate of decline of FEV1[17].treatment difference). Use of dornase alfa also reduced the
risk of exacerbations by 34% compared with placebo
(P=0.048). However, this study did not permit analysis of the
rate of decline in lung function due to limitations in study
size and duration. As the authors of the study pointed out, a
2-year trial comparing rates of decline in FEV1% predicted be-
tween treatment and placebo would have required 1500 patients
per arm to have 90% power to detect a 50% reduction in the
rate of decline [9]. Thus, the limited number of CF patients in
this age group precluded a study assessing rate of decline.
A more practical approach to evaluating the effect of treat-
ments on the rate of decline in lung function is to examine the
databases of large observational studies spanning several
years. The Epidemiologic Study of Cystic Fibrosis (ESCF) –
a prospective observational study with data from more than
24,000 patients with CF collected from 1994 to 2005 – has
provided a wealth of opportunities to evaluate the effects of
dornase alfa in clinical practice [35]. This study was designed
to collect detailed, longitudinal data regarding clinical care for
CF on an encounter-by-encounter basis at a large number of
treatment centers in the United States and Canada. The primary
objectives were to characterize the decline of lung function in
CF patients, rates of acute pulmonary exacerbations requiring
antibiotic therapy, and safety and effectiveness of long-term
treatment with dornase alfa [35].
In a recently published analysis of the association between
dornase alfa therapy and the rate of lung function decline,
2230 patients aged 8 to 38 years (mean age 14.5, baseline
FEV1 76.0% predicted) initially treated with dornase alfa
(index event) were compared with 5970 patients aged 8 to
38 years (mean age 14.5, baseline FEV1 86.6% predicted)
who had never used dornase alfa or had not started dornase
alfa for at least 4 years after enrollment in ESCF [18]. Patients
treated with dornase alfa were included in the analysis if they
had been enrolled in ESCF 2 years prior to the initiation of
dornase alfa (baseline period) and were recorded as receiving
dornase alfa for 2 subsequent years for ≥80% of visits. An
improvement in FEV1 was observed shortly after the initiation
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2.64% for ≥18-year-olds, both Pb0.001) but children in the
comparator group showed a significant decrease in FEV1 after
the index event (−0.67% predicted, Pb0.001). Adults in the
comparator group demonstrated a small decrease in lung func-
tion (−0.14% predicted, P=0.66) around a comparable index
event that was not statistically significant. These observations
confirm results from previous controlled clinical trials of
dornase alfa [7,9]. More importantly, a reduction in the mean an-
nual rate of FEV1 decline for the 2 years after the index event was
observed for children (32.1%, Pb0.001) and adults (28.8%,
P=0.068) in the dornase alfa group, although the difference did
not reach statistical significance for adult patients. By contrast,
the mean annual rate of decline significantly increased
(Pb0.001) for children in the comparator group, and did not
change (P=0.92) for adults in the comparator group (Fig. 5).
These results suggest that early initiation of therapy with
dornase alfa slows the rate of lung function decline in patients
with CF and has the theoretical potential to prolong survival.
These beneficial effects of early dornase therapy may relate to
its indirect effects on inflammation. In that regard, it is interest-
ing to note that the only other interventions thus far shown to
slow the rate of lung function decline in CF have been anti-
inflammatory therapies (high-dose ibuprofen and inhaled corti-
costeroids [ICS]). In the case of ibuprofen, observational data
from the Cystic Fibrosis Foundation Patient Registry revealed
a 29% reduction in the rate of decline of FEV1% predicted in
children aged 6–17 years treated with ibuprofen (n=1365) vs.
those not treated (n=8960) (Pb0.0001) [36]. This study of the
CFF registry with a large patient population supported the results
of a 4-year prospective clinical trial conducted in a smaller num-
ber of patients [37]. With regard to ICS, an analysis of observa-
tional data from ESCF examining the effect of ICS therapy in
2978 children aged 6 to 17 years also revealed a 29% reduction
in the rate of decline in FEV1% predicted after initiating ICS
[38]. These results are supported by a recent European observa-
tional study of the rate of lung function decline with ICS treat-
ment [39].Fig. 5. Annual rates of decline in FEV1% predicted before and after index PF4. Conclusions
The pathophysiology of CF is characterized by a continuous
cycle of obstruction, infection, and inflammation. Given the
role of the inflammatory process as a driver of irreversible
lung destruction, there is an increasing interest in exploring
the ability of therapies with anti-inflammatory effects to slow
disease progression when used early in the course of disease.
Dornase alfa has well-documented beneficial clinical effects
on the obstruction and infection components of the disease
process (improvement in lung function and decrease in the
rate of exacerbations requiring antibiotics), and has also
shown positive effects on markers of inflammation. In addition,
recent observational data from the ESCF study have suggested
that early initiation of dornase alfa can not only improve lung
function shortly after initiating therapy, but also can reduce
the rate of lung function decline over several years. Slowing
progression of lung disease should ultimately extend survival.
Results from a recent single-center cohort study of adult CF pa-
tients with low lung function (FEV1 b30% predicted) in the
United Kingdom suggests that the introduction of dornase alfa
as a chronic maintenance therapy is associated with improved
survival in patients with late-stage CF lung disease [40].
Additional data will be needed to determine whether this will
translate more generally into improved patient survival and
whether treatment initiated in infants and your children will
stabilize lung function over time. In the meantime, these
encouraging results concerning the long-term benefits of dor-
nase alfa therapy suggest a potentially greater role for this ther-
apy in the early treatment of CF.Conﬂict of interest statement
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